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http://djournal homepage: www.elsevier.com/locate/joaEditorialCatheter ablation as a class I recommendation therapy for symptomatic,
drug-resistant, paroxysmal atrial ﬁbrillationRecent clinical guidelines use 3 levels of recommendation for
procedures and therapies. Class I recommendations include condi-
tions with evidence and/or general agreement that a given proce-
dure/therapy is beneﬁcial, useful, and effective. Class II includes
those with conﬂicting evidence and/or a divergence of opinion about
usefulness/efﬁcacy, and class III those with evidence and/or general
agreement that a procedure/therapy is not useful or effective and in
some cases may be harmful. These classiﬁcations are further graded
by the levels at which the evidence is determined: when the data
are derived from multiple randomized clinical trials or meta-
analyses, the level of evidence is determined as A.
Catheter ablation is a non-pharmacological, non-surgical curative
therapy of cardiac arrhythmias, and its efﬁcacy and safety has been
established for supraventricular tachycardias and some ventricular
arrhythmias. Since the revolutionary ﬁnding by Haı¨ssaguerre et al.
in [1] that atrial ﬁbrillation (AF) is spontaneously initiated by ectopic
beats originating in the pulmonary veins (PV) [1], many reports have
demonstrated the efﬁcacy of catheter-based PV isolation, especially
in paroxysmal AF. The results of AF ablation have been substantially
improved by the development of technologies such as irrigation-tip
catheters and three-dimensional mapping systems.
To deﬁne the efﬁcacy and safety of AF ablation relative to
antiarrhythmic drug (AAD) therapy, several randomized studies
have been conducted [2–4]. In the ThermoCool trial in sympto-
matic paroxysmal AF patients in whom at least one AAD failed to
suppress AF recurrence, PV isolation resulted in signiﬁcantly
fewer AF recurrences than AAD, and was associated with better
quality of life and symptom severity scores [4]. Major treatment-
related adverse events were similar between the 2 groups. The
other studies also demonstrated superior results of ablation,
though major complications such as cardiac tamponade were
observed in some patients, and the long-term efﬁcacy of AF
ablation has not been established yet. Recent meta-analyses of
the randomized studies conﬁrmed the efﬁcacy of ablation com-
pared with AAD in patients with symptomatic drug-refractory
recurrent AF [5–7]. It should be pointed out that most studies had
exclusion criteria including patients with ejection fraction o40%,
left atrial diameter 45 cm, severe pulmonary disease, and recent
myocardial infarction, and the ablation procedures were done in
high-volume centers. Further, the patients included were rela-
tively young, and most of them suffered from paroxysmal AF.
With these limitations, however, the results of the randomized
trials and meta-analyses have encouraged us to elevate catheter
ablation to an established, effective therapy for symptomatic
drug-resistant paroxysmal AF in selected patients. This is also76/$ - see front matter & 2012 Japanese Heart Rhythm Society. Published by E
x.doi.org/10.1016/j.joa.2012.03.001based on the fact that the incidence of serious complications in AF
ablation, such as procedure-related death, is very low [8].
The Japanese Circulation Society (JCS) Guidelines for Non-
Pharmacological Therapy of Cardiac Arrhythmias have just been
revised and were published at the beginning of 2012 [9]. In this
revision, catheter ablation is recommended as a class I therapy for
maintaining sinus rhythm when the ablation procedure is done in
experienced centers with Z50 annual cases of AF ablation in
patients with symptomatic AAD-resistant paroxysmal AF who
have normal or mildly dilated left atria, normal or mildly reduced
left ventricular function, and no severe pulmonary disease. Thus,
we are now in a new era of treatment for AF, especially for
patients with paroxysmal AF. Continuous efforts should be made
to improve long-term outcomes after ablation while reducing
complication rates and procedure and ﬂuoroscopy times.
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